



RECEIVED
JUL 03 2001
PATENT
TECH CENTER 1000/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited in the United States Postal Service as first class mail in an envelope addressed to: BOX NON FEE AMENDMENT, Assistant Commissioner for Patents, Washington, D.C. 20231 on June 25, 2001.

Daniel S. Kasten
Reg. No. 45,363

In re application of: Johnson et al.	:	
Serial No.: 09/220,617	:	Examiner Robert C. Hayes
Filed: December 24, 1998	:	Group Art Unit 1647
For: Persephin and Related Growth Factors	:	
	:	

BOX NON FEE AMENDMENT
Assistant Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER

Enclosed please find:

1. Response to Notice to Comply; and
2. Marked-Up Versions and Clean Copies of Amended Specification and Figures.

It is believed that no fee is required. However, if this is incorrect and a fee is required, you are hereby authorized to charge any deficiencies or credit any overpayments to Deposit Account 18-1829. A duplicate copy of this letter is enclosed.

Respectfully submitted,

Daniel S. Kasten
Reg. No. 45,363
Howell & Haferkamp, L.C.
7733 Forsyth Boulevard, Suite 1400
St. Louis, Missouri 63105
(314) 727-5188

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

JUL 05 2001


TECH CENTER 1600/2900



St. Louis, Missouri
June 22, 2001

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited in the United States Postal Service as first class mail in an envelope addressed to: BOX NON FEE AMENDMENT, Assistant Commissioner for Patents, Washington, D.C. 20231 on June 25, 2001.


Daniel S. Kasten

19/G
B.G.J
4/29/02

In re application of:
Johnson et al.

Serial No.: 09/220,617

Filed: December 24, 1998

For: Persephin and Related Growth Factors

Examiner Hayes, Robert C.

Group Art Unit 1647

BOX NON FEE AMENDMENT
Assistant Commissioner for Patents
Washington, D.C. 20231

RESPONSE TO NOTICE TO COMPLY WITH 37 CFR § 1.821-1.825 AND 37 CFR 1.121 (a,b)

The following amendments and remarks are made in response to the Examiner's Communication, Paper No. 16, dated June 15, 2001.

IN THE SPECIFICATION:

The specification of the application has been amended as follows:

~~On page 10, line 4, after "(TGFβ1)" please add --(SEQ ID NO:150)--.~~

~~On page 10, line 5, after "(TGFβ2)" please add --(SEQ ID NO:151)--.~~

~~On page 10, line 6, after "(TGFβ3)" please add --(SEQ ID NO:152)--.~~

~~On page 10, line 6, after "(INHβA)" please add --(SEQ ID NO:153)--.~~